[ad_1]
Stockholm, July 7, 2021 /PRNewswire/ – Swedish orphan Biovitrum AB (publ) (Sobi™) presenting data at the 29th Congress of the Virtual ISTH 2021, International Society of Thrombosis and Hemostasis, 17 – July 21, 2021Received nine abstracts containing four treatments during ISTH, reflecting Sobi’s commitment to the rare disease community in the field of hematology. ISTH brings together the world’s leading experts to present the latest developments, exchange science and discuss clinical applications aimed at improving the care of hematology patients.
“In order to provide care and innovative treatments for people with rare blood diseases, we are very happy to share data on this year’s virtual ISTH,” Ravi Rao, Sobi R&D Director and Chief Medical Officer. “These data reflect our efforts to increase our knowledge and understanding of rare diseases.”
Real results of Alprolix® and Elocta®
The data will provide Alprolix (eftrenocog alfa) and Elocta (efmoroctocog alfa), both of which are prolonged half-life factor therapy for patients with hemophilia A and B. Sobi partnered with Sanofi to develop and commercialize Elocta and Alprolix.
oral expression
- The first interim analysis of a 24-month French, multicenter, prospective, non-interventional study to evaluate the practical use of half-life extended recombinant factor IX Fc fusion protein (rFIXFc) in patients with hemophilia B (B-SURE) And effectiveness). Session: Hemophilia: Real-World Data. Sunday, July 18 (11:00-12:00 US Eastern Time). # OC 08.1.
Electronic poster
- Interim analysis of the PREVENT study: real-world prospective data poster #PB0506 from children and adolescents with hemophilia A or B treated with recombinant factor VIII Fc (rFVIIIFc) or recombinant factor IX Fc (rFIXFc).
- The final result of ReITIrate-a prospective study of rescue immune tolerance induction (ITI) using recombinant factor VIII Fc (rFVIIIFc) in patients whose previous ITI attempts failed. Poster #PB0522. Joint with Sanofi.
- Use of rFIXFc in the real world Sweden: A report from the Swedish National Bleeding Disease Registry. Poster #PB0551.
- B-MORE, a baseline analysis of a 24-month prospective, non-interventional multicenter study on the actual effectiveness and use of recombinant factor IX Fc (rFIXFc) in hemophilia B. Poster #PB0552.
Real data on Doptelet® in the treatment of chronic immune thrombocytopenia
Sobi will submit three abstracts on the use of Doptelet (avatrombopag) in chronic immune thrombocytopenia (ITP), including those from United States.
oral expression
- Persistence of the platelet count response in patients receiving Avatrombopag for immune thrombocytopenia (ITP): post-hoc results of a phase 3 core and open label extension study. Wednesday, July 21 (13:00-14:00 US Eastern Time). Poster #OC 72.4.
Electronic poster
- Duration and persistence of thrombopoietin receptor agonist (TPO-RA) treatment in immune thrombocytopenia (ITP): real-world US claims analysis. Poster #PB0819.
- Conversion from Eltrombopag or Romiplostim to Avatrombopag in immune thrombocytopenia: a multicenter study in the United States…
The full story on Benzinga.com
[ad_2]
Source link
